Bicara Therapeutics develops dual-action cancer therapies that combine a bifunctional EGFR/TGF-β antibody with tumor microenvironment modulators to enhance treatment efficacy for solid tumors, particularly head and neck squamous cell carcinoma. This approach aims to improve patient outcomes by providing targeted therapies that offer meaningful and durable benefits.
Funding
$165M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BTFounders
Product
Problem
Many solid tumors, such as head and neck squamous cell carcinoma (HNSCC), are difficult to treat effectively due to the tumor microenvironment (TME) which can promote cancer cell survival and resistance to therapy. Current treatments often lack the ability to simultaneously target cancer cells and modulate the TME, limiting their efficacy and durability.
Solution
Bicara Therapeutics is developing dual-action cancer therapies that combine a bifunctional EGFR/TGF-β antibody with tumor microenvironment modulators. Their lead program, Ficerafusp alfa (BCA101), is a first-in-class antibody designed to simultaneously target the epidermal growth factor receptor (EGFR) on cancer cells and inhibit transforming growth factor-beta (TGF-β) signaling within the TME. By blocking both pathways, Ficerafusp alfa aims to directly inhibit cancer cell growth while also disrupting the immunosuppressive TME, potentially enhancing the effectiveness of treatment and improving patient outcomes. This approach is being investigated in multiple solid tumor types, including HNSCC.
Target Audience
The primary target audience includes patients with solid tumors, particularly head and neck squamous cell carcinoma (HNSCC), and the healthcare professionals who treat them, including oncologists and cancer centers.
Features
- Bifunctional antibody targeting both EGFR and TGF-β pathways
- Designed to directly inhibit cancer cell growth
- Modulates the tumor microenvironment to overcome immunosuppression
- Clinical development for multiple solid tumor cancer types, including head and neck squamous cell carcinoma (HNSCC)
- First-in-class dual-action mechanism